76 related articles for article (PubMed ID: 11498360)
1. Hypoxic cytotoxic agents: a new approach to cancer chemotherapy.
Brown JM
Drug Resist Updat; 2000 Feb; 3(1):7-13. PubMed ID: 11498360
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic cells in tumors as a target for cancer therapy.
Gali-Muhtasib HU; Diab-Assef M; Haddadin MJ
J Med Liban; 2002; 50(4):175-9. PubMed ID: 15298478
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-Specific Cytotoxins in Cancer Therapy.
Brown JM; Siim BG
Semin Radiat Oncol; 1996 Jan; 6(1):22-36. PubMed ID: 10717159
[TBL] [Abstract][Full Text] [Related]
4. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
5. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
6. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
8. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors as potential novel anticancer agents.
Dou QP; Li B
Drug Resist Updat; 1999 Aug; 2(4):215-223. PubMed ID: 11504494
[TBL] [Abstract][Full Text] [Related]
10. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
11. MR guided cancer treatment system for an elevated therapeutic index - a macroscopic approach.
Myhr G
Med Hypotheses; 2008; 70(3):665-70. PubMed ID: 17765401
[TBL] [Abstract][Full Text] [Related]
12. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia.
Cao X; Fang L; Gibbs S; Huang Y; Dai Z; Wen P; Zheng X; Sadee W; Sun D
Cancer Chemother Pharmacol; 2007 Mar; 59(4):495-505. PubMed ID: 16906425
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs.
Ackland SP; Peters GJ
Drug Resist Updat; 1999 Aug; 2(4):205-214. PubMed ID: 11504493
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
Harada H; Hiraoka M; Kizaka-Kondoh S
Cancer Res; 2002 Apr; 62(7):2013-8. PubMed ID: 11929818
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
16. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
17. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.
Primeau AJ; Rendon A; Hedley D; Lilge L; Tannock IF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8782-8. PubMed ID: 16361566
[TBL] [Abstract][Full Text] [Related]
18. Effects of HER-2/neu on chemosensitivity of tumor cells.
Järvinen TA; Liu ET
Drug Resist Updat; 2000 Dec; 3(6):319-324. PubMed ID: 11498399
[TBL] [Abstract][Full Text] [Related]
19. Significance of HIF-1-active cells in angiogenesis and radioresistance.
Harada H; Kizaka-Kondoh S; Li G; Itasaka S; Shibuya K; Inoue M; Hiraoka M
Oncogene; 2007 Nov; 26(54):7508-16. PubMed ID: 17563752
[TBL] [Abstract][Full Text] [Related]
20. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
